{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"ASLAN Pharmaceuticals Limited"},"Symbol":{"label":"Symbol","value":"ASLN"},"Address":{"label":"Address","value":"83 CLEMENCEAU AVENUE NO. 12-03 UE SQUARE, SINGAPORE, 239920, Singapore"},"Phone":{"label":"Phone","value":"+65 62224235"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Asia"},"CompanyDescription":{"label":"Company Description","value":"ASLAN Pharmaceuticals Ltd is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients. The company is evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease."},"CompanyUrl":{"label":"Company Url","value":"http://www.aslanpharma.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Alexandre Kaoukhov","title":"Chief Medical Officer"},{"name":"Carl Aslan Jason Morton Firth","title":"Chief Executive Officer &amp; Director"},{"name":"Kiran Kumar Asarpota","title":"Chief Operating Officer &amp; Head-Finance"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}